Enliven Therapeutics, Inc. (ELVN) Misses Q1 EPS by 23c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Nasdaq futures slip on chip weakness; S&P 500 holds gains
- Massive market rotation raises question: Is the sell-AI trade here to stay?
- Goldman sees major AI and data center policy implications from ‘blue tsunami’
- Nvidia chips stockpile in Hong Kong awaits China import approval - report
- Goldman says this FX trade is the best hedge for the AI drawdown
Tweet
Share
E-mailGet Alerts ELVN Hot Sheet
Join SI Premium – FREE
Enliven Therapeutics, Inc. (NASDAQ: ELVN) reported Q1 EPS of ($0.80), $0.23 worse than the analyst estimate of ($0.57).
For earnings history and earnings-related data on Enliven Therapeutics, Inc. (ELVN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ConocoPhillips beats third-quarter profit estimates
- Filana Therapeutics, Inc. (FLNA) Tops Q3 EPS by 3c
- Pyxis Oncology, Inc. (PYXS) Tops Q3 EPS by 4c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
